Predicting Response to Incretin Based Agents in Type 2 Diabetes
NCT ID: NCT01503112
Last Updated: 2018-04-19
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
957 participants
OBSERVATIONAL
2011-05-31
2014-04-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Study Hypothesis:
The investigators hypothesise that those who have low insulin secretion, as measured by post meal urine C-peptide Creatinine Ratio or blood C-peptide, will have poor blood glucose response to incretin based treatments.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Inhibition of Urinary Angiotensinogen and the Reduction of Blood Pressure by SGLT2 Inhibition in Patients With Type 2 Diabetes
NCT02796170
Prevention of Renal Failure in People Followed for Type 2 Diabetes in General Practice
NCT05749679
Effects of Dapagliflozin Treatment on Urinary Proteomic Patterns in Patients With Type 2 Diabetes
NCT02914691
Characterization of the Kinetics of Renal Glucose Reabsorption in Response to Dapagliflozin in Healthy Subjects and in Subjects With Type 2 Diabetes Mellitus (T2DM)
NCT01165268
Incretin-based Drugs and the Risk of Heart Failure
NCT02456428
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Patients starting incretin treatments
Patients starting GLP-1 agonists or DPPIV inhibitors as part of their normal clinical care.
No intervention, observational study
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
No intervention, observational study
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* HbA1c \>= 58mmol/mol
Exclusion Criteria
* Renal failure as shown by a eGFR (estimated glomerular filtration rate) less than 30 mL/min/1.73m2
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
National Institute for Health Research, United Kingdom
OTHER_GOV
University of Exeter
OTHER
Royal Devon and Exeter NHS Foundation Trust
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Angus Jones
NIHR Doctoral Research Fellow
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Andrew T Hattersley
Role: STUDY_DIRECTOR
University of Exeter Medical School/Royal Devon and Exeter Hospital NHS Foundation Trust
Angus Jones
Role: PRINCIPAL_INVESTIGATOR
University of Exeter Medical School/Royal Devon and Exeter Hospital NHS Foundation Trust
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Cornwall and Isles of Scilly NHS Primary Care Trust
Truro, Cornwall, United Kingdom
North Devon NHS Trust
Barnstaple, Devon, United Kingdom
Royal Devon and Exeter NHS Foundation Trust
Exeter, Devon, United Kingdom
Plymouth Hospitals NHS Trust
Plymouth, Devon, United Kingdom
South Devon Healthcare NHS Foundation Trust
Torbay, Devon, United Kingdom
Taunton and Somerset NHS Foundation Trust.
Taunton, Somerset, United Kingdom
Yeovil Disctrict Hospital NHS Foundation Trust
Yeovil, Somerset, United Kingdom
The Royal Bournmouth and Christchurch Hospitals NHS Trust
Bournmouth, , United Kingdom
North Bristol NHS Trust
Bristol, , United Kingdom
Ipswich Hospital NHS Trust
Ipswich, , United Kingdom
Northampton General Hospital NHS Trust
Northampton, , United Kingdom
Oxford Radcliffe Hospitals NHS Trust
Oxford, , United Kingdom
Portsmouth Hospitals NHS Trust
Portsmouth, , United Kingdom
Surrey and Sussex Healthcare NHS trust
Redhill, , United Kingdom
East Sussex Healthcare NHS Trust
Saint Leonards-on-Sea, , United Kingdom
University Hospitls North Staffordshire NHS Trust
Stoke-on-Trent, , United Kingdom
South Warwickshire NHS Foundation Trust
Warwick, , United Kingdom
West Hertfordshire Hospitals NHS Trust
Watford, , United Kingdom
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Jones AG, McDonald TJ, Shields BM, Hill AV, Hyde CJ, Knight BA, Hattersley AT; PRIBA Study Group. Markers of beta-Cell Failure Predict Poor Glycemic Response to GLP-1 Receptor Agonist Therapy in Type 2 Diabetes. Diabetes Care. 2016 Feb;39(2):250-7. doi: 10.2337/dc15-0258. Epub 2015 Aug 4.
Dennis JM, Shields BM, Hill AV, Knight BA, McDonald TJ, Rodgers LR, Weedon MN, Henley WE, Sattar N, Holman RR, Pearson ER, Hattersley AT, Jones AG; MASTERMIND Consortium. Precision Medicine in Type 2 Diabetes: Clinical Markers of Insulin Resistance Are Associated With Altered Short- and Long-term Glycemic Response to DPP-4 Inhibitor Therapy. Diabetes Care. 2018 Apr;41(4):705-712. doi: 10.2337/dc17-1827. Epub 2018 Jan 31.
Jones AG, Shields BM, Hyde CJ, Henley WE, Hattersley AT. Identifying good responders to glucose lowering therapy in type 2 diabetes: implications for stratified medicine. PLoS One. 2014 Oct 23;9(10):e111235. doi: 10.1371/journal.pone.0111235. eCollection 2014.
Related Links
Access external resources that provide additional context or updates about the study.
Research group website
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
11233581
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.